Biotech website design and development.

Our WordPress builds start from $500 for a focused 5-page site. Most biotech companies need the Growth scope, from $1,470, because pipeline, science, team and investor pages plus custom design add up quickly. Larger sites with publication libraries, investor feeds or headless builds start at $2,940. Every project gets a fixed price after a free 30-minute consultation.

A standard build takes 4–5 weeks from kickoff to launch. Biotech projects often run longer because content goes through scientific, legal and regulatory review, so we plan review rounds into the timeline from the start rather than treating them as delays.

Yes. We build biotech and life science online stores on WordPress and WooCommerce: product catalogues searchable by name and catalogue number, family-specific technical fields, pack sizes on one product page, Add to Cart or Request a Quote per product, datasheet and protocol downloads, customer accounts, Stripe checkout and bulk CSV product upload. Live courier rates, tax-exempt approval and customer-specific pricing can be added later without a rebuild.

Yes. We share page drafts in a format reviewers can annotate, keep a record of approved copy, and set up the CMS so new claims can be drafted and reviewed before they go live. We do not write or approve scientific or regulatory claims ourselves; your reviewers stay the final say on every statement.

Most biotech marketing websites do not handle protected health information, so HIPAA usually does not apply to them. If yours collects patient details, for example through a clinical-trial interest form, those submissions need a HIPAA-eligible form and storage provider with a business associate agreement. We will flag where that applies and build the form on a suitable service, but compliance itself is a decision for your legal team.

WordPress with custom blocks suits most biotech companies: your team can update news, publications and careers without a developer. A headless build with Next.js makes sense when the site must pull data from other systems, such as an investor-relations feed or a trial database, or when the brand needs highly interactive science explainers. We recommend one in the proposal and explain why.

Yes. We build pipeline pages that are easy to update as programmes move between stages, searchable publication and poster libraries, and investor sections for press releases, events and presentations. For listed companies, SEC filings and stock data can be pulled in from an investor-relations provider.

We structure the content and write the supporting copy, page introductions and calls to action. The science itself should come from your team, because it has to be accurate and approved. We turn it into pages that non-specialists, such as investors and recruits, can follow.